Sanofi-Aventis To Consolidate Further In India As Longtime Shareholder United Breweries Exits
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian liquor baron Vijay Mallya's move to sell the 10.27 percent stake that his group companies hold in the Indian unit of Paris-headquartered Sanofi-Aventis will give the multinational drug maker an "opportunity to consolidate its presence in the high-growth market," and is not seen as part of any plans to de-list the company from the Indian stock exchanges
You may also be interested in...
Sanofi-Aventis India Managing Director Shailesh Ayyangar On Building Infrastructure To Bring Affordable Drugs To Patients In Rural Markets: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis Managing Director Shailesh Ayyangar faces the daunting challenge of creating a new paradigm in the rural centers of India. In a rare interview, Ayyangar spoke to PharmAsia News' India Bureau about the company's rural markets strategy, creating brands, doing deals and about buying out "strategically important" companies.
Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent
MUMBAI - After Novartis and Mylan, it's now Pfizer's turn to increase its equity holding in its Indian operations. In an announcement to the Bombay Stock Exchange, Pfizer said it has decided to acquire an additional stake of 33.77 percent in Pfizer India through an open offer from public shareholders at a price of 675 rupees per share ($13.23)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).